The Price Tag on Progress — Chemotherapy for Colorectal Cancer
During the past decade, the Food and Drug Administration (FDA) has approved five new drugs for metastatic colorectal cancer.
Originally published on 07/22/2014 in New England Journal of Medicine
Dr. Deborah Schrag of Dana-Farber Cancer Institute notes that the prices for colorectal cancer treatments are rising faster than their improvements in effectiveness and argues for a restructuring of the policies that have allowed this unchecked escalation.
Read the full article here.